Perceptive Advisors LLC Increases Holdings in Caris Life Sciences, Inc. $CAI

Perceptive Advisors LLC increased its holdings in shares of Caris Life Sciences, Inc. (NASDAQ:CAI) by 3.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,136,206 shares of the company’s stock after purchasing an additional 38,043 shares during the period. Perceptive Advisors LLC owned 0.40% of Caris Life Sciences worth $30,655,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. MetLife Investment Management LLC boosted its position in Caris Life Sciences by 84.0% in the 4th quarter. MetLife Investment Management LLC now owns 1,654 shares of the company’s stock valued at $45,000 after buying an additional 755 shares during the last quarter. Global Retirement Partners LLC boosted its position in Caris Life Sciences by 99,900.0% in the 4th quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock valued at $27,000 after buying an additional 999 shares during the last quarter. Olistico Wealth LLC purchased a new position in Caris Life Sciences in the 4th quarter valued at about $31,000. Police & Firemen s Retirement System of New Jersey boosted its position in Caris Life Sciences by 15.0% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 11,932 shares of the company’s stock valued at $322,000 after buying an additional 1,560 shares during the last quarter. Finally, PEAK6 LLC boosted its position in Caris Life Sciences by 6.9% in the 4th quarter. PEAK6 LLC now owns 24,800 shares of the company’s stock valued at $669,000 after buying an additional 1,600 shares during the last quarter.

Wall Street Analyst Weigh In

CAI has been the subject of a number of analyst reports. Wolfe Research cut shares of Caris Life Sciences from an “outperform” rating to a “peer perform” rating in a research report on Monday, June 1st. Weiss Ratings raised shares of Caris Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. JPMorgan Chase & Co. reduced their price target on shares of Caris Life Sciences from $35.00 to $30.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Jefferies Financial Group started coverage on shares of Caris Life Sciences in a research report on Monday, April 13th. They set a “buy” rating and a $28.00 price target on the stock. Finally, Piper Sandler started coverage on shares of Caris Life Sciences in a research report on Friday, April 10th. They set a “neutral” rating and a $21.00 price target on the stock. Six investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Caris Life Sciences currently has an average rating of “Hold” and an average target price of $27.56.

Insiders Place Their Bets

In other Caris Life Sciences news, Director Jeff L. Vacirca acquired 31,050 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were purchased at an average price of $16.15 per share, for a total transaction of $501,457.50. Following the completion of the purchase, the director directly owned 49,671 shares in the company, valued at $802,186.65. The trade was a 166.75% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 50.00% of the stock is currently owned by company insiders.

Caris Life Sciences Stock Performance

Shares of CAI stock opened at $17.86 on Thursday. The company has a quick ratio of 6.52, a current ratio of 7.05 and a debt-to-equity ratio of 0.64. Caris Life Sciences, Inc. has a one year low of $14.19 and a one year high of $42.50. The stock’s 50-day moving average is $17.72. The company has a market capitalization of $5.05 billion and a PE ratio of -2.35.

Caris Life Sciences announced that its board has authorized a stock repurchase program on Monday, June 8th that allows the company to buyback $100.00 million in outstanding shares. This buyback authorization allows the company to buy up to 2.2% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its shares are undervalued.

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.